StemCells: Spinal Injury Gains Are Sustained After One Year
By Catherine Shaffer
Wednesday, February 13, 2013
StemCells Inc. reported positive results from the first patient cohort of a Phase I/II trial of its human neural stem cell product for spinal cord injury, and investors responded enthusiastically, driving the Newark, Calif.-based company's stock up 21 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.